Rate Of Adverse Reactions To COVID Vaccines Already 50x

New Post Public Reply Private Reply Replies (0) Message Board
Rusty
209
Rate Of Adverse Reactions To COVID Vaccines Already 50x Higher Than Flu Shot

With reports this morning of another otherwise-healthy patient dying suddenly after receiving her first dose of a COVID-19 vaccine, many skeptics in both Europe and the US still have serious reservations about the jabs, even as big pharma and their allies in the US and British governments insist that they are 100% safe. Everyone claiming otherwise is not only wrongheaded, but acting in a deliberately malicious manner.

s new questions about efficacy and timing arise, independent journalist Alex Berenson, one of the most prominent skeptics of lockdowns and masks in the US, noted in a twitter thread earlier on Tuesday that the percentage of patients experiencing severe or potentially life-threatening reactions to the COVID-19 vaccines could be much higher than the data collected by the CDC are letting on.

The CDC's VAERS reporting system was set up to track vaccine-related injury, Most patients can expect to experience some kind of adverse reaction, but for the vast majority of patients, symptoms will be relatively mild and clear up within a couple of days. But amid a rush of reports about patient deaths, Berenson points out that the number of patients seeing serious complications per the number of doses distributed is roughly 50x higher than the rate of 'adverse' reactions caused by the flu vaccine.

1/ Through Dec. 22, with fewer than 1 million doses of the #Covid vaccine given, @cdcgov's vaccine injury reporting system received 307 reports of ER visits and 17 "life threatening" events.

Per dose, that's roughly 50 times the rate of adverse events from the flu vaccine...

— Alex Berenson (@AlexBerenson) January 5, 2021
2/ In 2019-2020, about 175 million flu vaccine doses were given. 1220 ER visits and 73 "life threatening" events were reported. The data is on the CDC VAERS Website.

Caveats: physicians et al may be more diligent about reporting #Covid vaccine events, since the vaccine is new...

— Alex Berenson (@AlexBerenson) January 5, 2021
3/ And the data is theoretically updated through Friday Jan. 1, which would be a much higher denominator. However, I believe it is correct to use Dec. 22 as the last date for Covid adverse events because I cannot find any later reports in the system...

— Alex Berenson (@AlexBerenson) January 5, 2021
Berenson also speculated that this number might be even higher due to possible delays in updating the CDC's data sets. This would seemingly confirm rates of adverse reactions seen during clinical trials. What's more, clinical trials, generally speaking, tend to "UNDERSTATE" unpleasant or unwanted side effects, while they "OVERSTATE" the drug's efficacy.

4/ Plus, the first Covid vaccine doses have mostly been given to healthy people in settings where problems can be quickly treated. These problems are occurring BEFORE the rollout to older, less healthy people - and before the 2nd dose, which is known to be far more dangerous...

— Alex Berenson (@AlexBerenson) January 5, 2021
5/ And this merely confirms what the clinical trials showed (in general, though not always, clinical trials tend to UNDERSTATE real world problems and OVERSTATE efficacy, because any smart drug company will try to bias the trials in its favor).

— Alex Berenson (@AlexBerenson) January 5, 2021
For readers who are so inclined, Berenson shared a link to the CDC data, which isn't exactly easy to find on the agency's website.

The data is here, and fairly straightforward to query.https://t.co/qOp5zS7cYB

— Alex Berenson (@AlexBerenson) January 5, 2021
Meanwhile, the US, UK and Europe are all lagging behind vaccination targets, while Russian President Vladimir Putin recently suggested that Russia might jump on the "Immunity Passport" bandwagon.

Berenson recently sat for an interview with Joe Rogan on Rogan's popular podcast, where the longtime journalist discussed other misconceptions about the "science" behind COVID-19, including questioning the US death toll.

[YT]goZQ6iOIFYo[/YT]

https://www.zerohedge.com/covid-19/rate-adver...r-flu-shot
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 4

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 4

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Vaccinex Unveils Efficacy Insights for Pepinemab in Alzheimer’s Study

Updated Category News Views 71

Vaccinex Provides Update on Pepinemab Study for Alzheimer’s Disease ROCHESTER, N.Y. — Vaccinex, Inc. (NASDAQ: VCNX), a forward-thinking biotechnology firm, is making significant strides in the treatment of Alzheimer's disease (AD) and cancer. The company is focused on a unique approach through the inhibition of Semaphorin 4D (SEMA4D). Recently, it was announced that...

Continue Reading
Legal Inquiry into Netflix, Inc. (NFLX) Attracts Investor Attention

Updated Category News Views 287

Understanding the Investigation into Netflix, Inc. Recently, the law firm Robbins Geller Rudman & Dowd LLP has initiated a formal investigation into Netflix, Inc. (NASDAQ: NFLX). This inquiry primarily focuses on potential violations of U.S. federal securities laws that may have occurred within the company. The Implications for Investors This investigation comes at a...

Continue Reading
Norway's Wealth Fund Expands Portfolio with London Investment

Updated Category News Views 221

Norway's Sovereign Wealth Fund Takes Bold Step in London Norway's sovereign wealth fund, expertly managed by Norges Bank Investment Management, has recently made headlines with its strategic acquisition of a 25% stake in a notable portfolio of office and retail properties located in London's prestigious Mayfair district. Significant Investment in a Prime Location This...

Continue Reading
Exagen Inc. Announces New Biomarkers and Financial Success

Updated Category News Views 291

Exagen Inc. Introduces Groundbreaking Biomarkers for Autoimmune Diseases Innovative testing aims to enhance patient diagnosis and care Exagen Inc. (Nasdaq: XGN), a pioneering company in autoimmune testing, has achieved a significant milestone by receiving conditional approval from the New York State Department of Health for its advanced assays to diagnose systemic lupus...

Continue Reading
Pacaso's Financial Growth in 2025: A Closer Look At Results

Updated Category News Views 1306

Pacaso Shows Promising First Half Financial Performance Pacaso, the innovative platform for co-owned luxury vacation homes, has recently shared its financial results for the first half of 2025, demonstrating strong stability and improved efficiency despite a challenging broader housing market. The company reported an impressive adjusted gross profit while managing to...

Continue Reading